Safety issues in vasculitis: infections and immunizations in the immunosuppressed host

Infectious diseases are a significant cause of morbidity and mortality in immunosuppressed patients, including those with connective tissue diseases. Both disease and treatment contribute to a predisposition to infection in immunocompromised patients. Significant infection and morbidity occur in 25%...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cleveland Clinic journal of medicine Ročník 79 Suppl 3; s. S38
Hlavní autor: Isada, Carlos M
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.11.2012
Témata:
Aspergillosis - complications
Aspergillosis - diagnosis
Aspergillosis - prevention & control
Connective Tissue Diseases - complications
Connective Tissue Diseases - drug therapy
Herpes Zoster - complications
Herpes Zoster - diagnosis
Herpes Zoster - prevention & control
Histoplasmosis - complications
Histoplasmosis - diagnosis
Histoplasmosis - prevention & control
Humans
Immunocompromised Host
Immunosuppressive Agents - adverse effects
JC Virus
Nocardia Infections - complications
Nocardia Infections - diagnosis
Nocardia Infections - prevention & control
Opportunistic Infections - complications
Opportunistic Infections - diagnosis
Opportunistic Infections - prevention & control
Pneumocystis Infections - complications
Pneumocystis Infections - diagnosis
Pneumocystis Infections - prevention & control
Polyomavirus Infections - complications
Polyomavirus Infections - diagnosis
Polyomavirus Infections - prevention & control
Vasculitis - complications
Vasculitis - drug therapy
ISSN:1939-2869, 1939-2869
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Infectious diseases are a significant cause of morbidity and mortality in immunosuppressed patients, including those with connective tissue diseases. Both disease and treatment contribute to a predisposition to infection in immunocompromised patients. Significant infection and morbidity occur in 25% to 50% of these patients with a median mortality of 5.2% due to common bacterial infections, such as pneumonia or bacteremia, and opportunistic fungal infections such as Pneumocystis. The lungs, skin, urinary tract, blood, and central nervous system are commonly affected. Pathogens such as Pneumocystis jirovecii, Histoplasma capsulatum, Aspergillus species, herpes zoster, JC virus, Nocardia asteroides, and Nocardia species are increasingly prevalent in immunocompromised patients. Improved recognition, diagnosis, and prevention of these infections are needed to enhance outcomes in these patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1939-2869
1939-2869
DOI:10.3949/ccjm.79.s3.09